Literature DB >> 8548360

The influence of a peptide sequence from PF-4 (CT-112) on type II collagen-induced arthritis in mice.

P H Wooley1, J D Whalen, J A Dutcher, D F Counts.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8548360     DOI： 10.1007/bf01778294

Source DB:  PubMed          Journal:  Inflamm Res        ISSN： 1023-3830            Impact factor:   4.575


× No keyword cloud information.
  8 in total

1.  Effects of indomethacin, cyclosporin, cyclophosphamide, and placebo on collagen-induced arthritis of mice.

Authors:  G W Cannon; S McCall; B C Cole; M M Griffiths; L A Radov; J R Ward
Journal:  Agents Actions       Date:  1990-03

2.  Collagen-induced arthritis in the mouse.

Authors:  P H Wooley
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

3.  Anti-inflammatory activity of an orally active peptide sequence from PF-4 on acute inflammation and DTH.

Authors:  J E Talmadge; L S Kelsey; G S Brown; D F Counts
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

4.  Gold does not alter the arthritic, humoral, or cellular responses in rats with type II collagen-induced arthritis.

Authors:  W J McCune; D E Trentham; J R David
Journal:  Arthritis Rheum       Date:  1980-08

5.  Evaluation of the effects of various anti-arthritic drugs on type II collagen-induced mouse arthritis model.

Authors:  K Phadke; R L Fouts; J E Parrish; L D Butler
Journal:  Immunopharmacology       Date:  1985-08

6.  Effect of cyclophosphamide, hydrocortisone and levamisole on collagen-induced arthritis in rats.

Authors:  J M Stuart; L K Myers; A S Townes; A H Kang
Journal:  Arthritis Rheum       Date:  1981-06

7.  Effects of cyclosporin on collagen induced arthritis in mice.

Authors:  K Takagishi; N Kaibara; T Hotokebuchi; C Arita; M Morinaga; K Arai
Journal:  Ann Rheum Dis       Date:  1986-04       Impact factor: 19.103

8.  Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates.

Authors:  P H Wooley; H S Luthra; J M Stuart; C S David
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307
  8 in total
  1 in total

1.  Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis.

Authors:  Robert J Barry; Mohammad O Tallouzi; Nick Bucknall; Jonathan M Mathers; Philip I Murray; Melanie J Calvert; David J Moore; Alastair K Denniston
Journal:  Cochrane Database Syst Rev       Date:  2018-12-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.